HIV

Latest News

Once Monthly Oral PrEP Medication Will Advance to Phase 3 Study
Once Monthly Oral PrEP Medication Will Advance to Phase 3 Study

July 16th 2025

Investigators find that the phase 2 trial supports the further development of MK-8527 as an HIV pre-exposure prophylaxis.

FDA to Evaluate Merck’s Doravirine, Islatravir Regimen for HIV-1
FDA to Evaluate Merck’s Doravirine, Islatravir Regimen for HIV-1

July 10th 2025

FDA Approves Lenacapavir for Prevention of HIV
FDA Approves Lenacapavir for Prevention of HIV

June 18th 2025

Home Administration of Long-Acting HIV Therapy is Safe, Effective
Home Administration of Long-Acting HIV Therapy is Safe, Effective

May 3rd 2025

Gilead Presents Data Demonstrating Established, Investigational HIV Drugs
Gilead Presents Data Demonstrating Established, Investigational HIV Drugs

March 15th 2025

More News

© 2025 MJH Life Sciences

All rights reserved.